8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

Form 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 19, 2021  

RenovaCare, Inc.
(Exact Name of Registrant as Specified in Charter)

Nevada	000-30156	98-0384030
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

4 Becker Farm Road, Suite 105, Roseland, NJ 07068

(Address of Principal Executive Offices) (Zip Code)

(888) 398-0202
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
	[   ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[   ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	[   ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class Trading Symbol(s) Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [   ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

Section 7 Regulation FD

Item 7.01. Regulation FD Disclosure.

On January 19, 2021 management of RenovaCare, Inc. (the "Company") presented at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 (the “NobleCon Presentation”).

By furnishing this Current Report on Form 8-K (the “Current Report”) and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the NobleCon Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.  The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The press release announcing the NobleCon Presentation and the PowerPoint presentation utilized during the 2020 Investor Presentation Forum (the “Presentation”) are attached as, respectively, Exhibits 99.1 and 99.2 to this Current Report.

The information presented in Item 7.01 of this Current Report and Exhibits 99.1 and 99.2 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Section 9 Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

Number
99.1	Press release dated January 19, 2021 titled "RenovaCare to Present at Noble Capital Markets Annual Investor Conference on January 19, 2021"
99.2	Presentation materials utilized during RenovaCare, Inc.’s NobleCon Presentation

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on January 20, 2021.

RenovaCare, Inc.
By:	/s/ Alan L. Rubino
	Alan L. Rubino
	President and Chief Executive Officer

EX-99.1 2 exh_991.htm PRESS RELEASE

EXHIBIT 99.1

RenovaCare to Present at Noble Capital Markets Annual Investor Conference on January 19, 2021

ROSELAND, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19 at 5:15pm EST. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com.

A high-definition, video webcast of the presentation will be available the following day on the Company’s website www.renovacareinc.com.

About RenovaCare
RenovaCare, Inc. is developing new generation autologous stem cell therapies for the regeneration of human organs and tissues. The Company’s initial product under development targets the body’s largest organ, the skin. The Company’s flagship technology, the CellMist™ System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist™ System facilitates rapid healing of wounds or other afflicted tissues when applied topically as a gentle cell mist using the patented RenovaCare SkinGun™. The Company’s SkinGun™ is used to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – on to wounds.

Development for next-generation biomedical technologies and devices for addressing unmet medical needs and commercialization is taking place at the RenovaCare R&D Innovation Center, located at StemCell Systems in Berlin, Germany. The Innovation Center houses dedicated RenovaCare cell biology laboratories; additional engineering, fabrication, prototyping and performance testing facilities; and product design studios for medical devices and biomedical products. Experienced contract bioengineers, cell biologists, and support staff work under the direction of a team of MD-PhDs who are experts in regenerative medicine, new product development, and clinical translation.

RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

For additional information, please call Amit Singh at: 1-888-398-0202 or visit: https://renovacareinc.com.

To receive future press releases via email, please visit:
https://renovacareinc.com/investors/register/.
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/.
Follow us on Twitter: https://twitter.com/RenovaCareInc.
Follow us on Facebook: https://www.facebook.com/renovacarercar.

About Noble Capital Markets, Inc.
Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed and registered broker-dealer Noble provides institutional-quality equity research, merchant and investment banking, wealth management and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade+. In 2018 Noble launched www.channelchek.com – an investment community dedicated exclusively to small and micro-cap companies and their industries. Channelchek is tailored to meet the needs of self-directed investors and financial professionals and is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 emerging growth companies are listed on the site, with growing content including webcasts, industry sector reports, advanced market data and balanced news.

Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.

We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:

• LinkedIn
• Facebook
• Twitter

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e7e19912-983e-4988-bf55-295f83240b70

EX-99.1

EdgarFiling

EX-99.2

Exhibit 99.2

1 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 CellMist™ & SkinGun™ Symbol: RCAR RenovaCare | Noble Capital Markets 17 th Annual Investor Conference January 19, 2021 Next Generation Cell Isolation & Ultra - Gentle Cell Spray

2 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 This slide deck and the accompanying oral presentation contain forward - looking statements, including, but not limited to, statements related to RenovaCare Inc . ’s future financial and operating results, including 2020 financial guidance, 2021 goals and expectations for growth ; the company’s corporate development efforts ; the company’s growth strategy ; future product sales and volume ; planned sales and marketing and related efforts ; future inventory and supply challenges ; planned, ongoing and future clinical trials and other product development activities ; planned regulatory submissions ; ongoing and future product launches ; the timing of such events and activities ; and other statements that are not historical facts . These forward - looking statements are based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties . Actual results and the timing of events could differ materially from those anticipated in such forward - looking statements as a result of these risks and uncertainties, which including, without limitation, risks and uncertainties associated with : maintaining or increasing sales and revenue ; effectively commercializing the company’s products and product candidates ; the time - consuming and uncertain regulatory approval process, including the risk that the company’s current and planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all ; the effectiveness of the license agreement ; costly and time - consuming product development and the uncertainty of clinical success, including risks related to failure or delays in initiating or completing clinical trials ; protecting and enhancing the company’s intellectual property rights ; delays or problems in the supply or manufacture of the company’s products or product candidates ; the company’s ability to maintain rights to its products and product candidates ; complying with applicable U . S . and non - U . S . regulatory requirements ; government investigations and other actions ; obtaining and maintaining adequate coverage and reimbursement for the company’s products ; identifying and acquiring, in - licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired businesses ; the company’s ability to realize the anticipated benefits of its collaborations with third parties for the development of product candidates ; the ability to achieve future financial performance and results and the uncertainty of future tax and other provisions and estimates ; and other risks and uncertainties affecting the company, including those described from time to time under the caption “Risk Factors” and elsewhere in RenovaCare Inc . ’s Securities and Exchange Commission filings and reports (Commission File No . 000 - 30156 , including the company’s Quarterly Report on Form 10 - Q for the quarter ended September 30 , 2020 and future filings and reports by the company . Other risks and uncertainties of which the company is not currently aware may also affect the company’s forward - looking statements and may cause actual results and the timing of events to differ materially from those anticipated . The forward - looking statements made in this slide deck and the accompanying oral presentations are made only as of the date hereof or as of the dates indicated in the forward - looking statements, even if they are subsequently made available by the company on its website or otherwise . The company undertakes no obligation to update or supplement any forward - looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward - looking statements were made . Forward - Looking Statements “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

3 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Alan L. Rubino Chairman & CEO Robin A. Robinson, PhD Chief Scientific Officer Today’s Presenters

4 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare, Inc. (RCAR) is a biotechnology company focused on developing first - of - kind autologous (self - donated) stem cell therapies for the regeneration of human organs. Our initial products under development target the body’s largest organ, the skin. Our flagship technology, the CellMist™ System, uses our patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. Currently under Conditional IDE status with the FDA for second degree burn patients, our platform therapies target an estimated 143 million patients worldwide who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases. About RenovaCare

5 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Development at StemCell Systems: SkinGun™ Cell Spray Device CellMist™ Cell Isolation Process Historical: Discovery Current: Clinical Future: Commercial Technology Evolution Company Focus Electronic SkinGun™ Disposable SkinGun™ CellMist™ System Closed Cell Isolation Device Advanced Regeneration Therapies • Other Tissues (Adipose, etc.) • Skin Other Clinical Indications Burn, Wound & Other Therapies Strategic Partnerships Product Collaborations Early Research & Development Intellectual Property RenovaCare Launch 70+ Human Case Studies Advanced Research & Development Clinical Trial Program Intellectual Property Regulatory Submissions Corporate Development RenovaCare: Past, Present and Future

6 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 DIVERSE PRODUCT PORTFOLIO Burns, chronic wounds, acute wounds and scars ; regeneration of skin and other organs and tissues DISCIPLINED CAPITAL ALLOCATION Balanced to support portfolio growth opportunities, financings, corporate development and shareholder returns ROBUST, EXPANDING IP ESTATE Defensible, growing intellectual property and R&D portfolio in core areas focused on differentiated products for unmet needs EXECUTING GROWTH STRATEGY Portfolio growth in key therapeutic areas strategic partnerships , operational efficiency and world - class leadership Focused Strategies to Meet Long - Term Objectives SPRAYING SELF - DONATED STEM CELLS TO REGENERATE TISSUES & ORGANS

7 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Next - Generation Biomedical Technologies Devices & Products

8 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Grafting is Painful, Expensive and Leaves Scarring Skin Grafting is Current Standard - of - Care Painful & Lengthy Treatment Cycle › 200 - year old method with the last breakthrough 50 years ago › Large sheets of skin are surgically removed and re - stitched onto wound › Painful procedure that leaves extensive scarring › Grafted skin is not naturally pliable Expensive, Drug Dependent Psychologically Damaging › Creates new wounds from donor sites and requires multiple surgeries › Requires wound management for donor and target sites, while in hospital › Extensive pain management and physical and psychological therapy › Life - long physical and emotional scarring Sheets of meshed skin for surgical stitching Mesh scars in skin graft patient The current standard of care is expensive, lengthy and painful; resulting in multiple surgeries and extended hospital stays. INADEQUATE OPTIONS FOR BURN PATIENTS

9 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Step 1: Examine Wound/Harvest Donor Skin Tissue Performed bedside by the surgical burn team (15 min.) Step 2: Cell Isolation by Enzymatic Digestion in Cell Isolation Device Performed by burn tech (90 min.) Step 3: Cell Suspension Verification Performed by burn tech (5 min.) Step 4: Cell Spraying onto Wound with SkinGun Spray Device Performed in OR by burn surgeon (10 min.) RenovaCare Cell Isolation & SkinGun Procedure SIMPLE FOUR - STEP PROCESS IN LESS THAN THREE HOURS 1 2 3 4

10 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare SkinGun™ Technology *Treated under special innovative practice approach at: Berlin - Brandenburg Center for Regenerative Therapies, Charité Berlin; and under innovative practice approach at UPMC Medical Center, Pittsburgh, Pennsylvania. **Raw patient data available. 70+ Patients Successfully Treated* SELF - HEALING. SCAR - FREE. SPRAY - ON WOUND CARE.

11 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare Breakthrough Technology CellMist™ uses donor tissue sample. RenovaCare CellMist ™ Split Thickness Skin Graft 10cm 2 donor sample Donor Skin Sample 10cm 2 Typical › Small donor skin sample taken under local anesthetic › 90 minutes to harvest regenerative autologous stem cells › Water - based suspension of cells sprayed onto wound Natural Skin Growth › Treatment areas virtually indiscernible from untreated skin › No hypertrophic scars, contracture, or functional impairment › Complete re - epithelialization and full range of movement Quick Healing & Reduced Hospitalization/Follow - On Visits › 6 - 10 days for re - epithelialization and patient discharge › Versus weeks/months for skin graft patients Split Thickness Mesh Graft 1:100* 1:3 – 1:9* 1:1* Donor Area Donor Area Burn Area Burn Area Burn Area Traditional skin grafts require large sheets of surgically removed skin. THE CELLMIST™ SYSTEM AND SKINGUN™

12 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 IDE/PMA 510(k) 510(k) 510(k) CellMist System™ Electronic SkinGun™ Autologous Skin Stem Cell Therapy for Burns POTENTIAL APPROVALS FROM 2021 - 2025 Disposable SkinGun™ Cell Spray Deposition Device Electronic SkinGun™ Cell Spray Deposition Device Cell Isolation Device Multi - Tissue Automated Closed System onsite, rapid cell isolation and spray | multiple cell types | tissues and organs, beyond skin Our Execution Will Lead To Four Major Submissions for Approval RENOVACARE PRODUCT PORTFOLIO: 3 SELECT MULTI - TISSUE CELL THERAPY PLATFORMS

13 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 The RenovaCare Electronic SkinGun™ OUR PATENTED CELL SPRAY TECHNOLOGIES SPRAY - ON STEM CELLS FOR RAPID HEALING Ultra - Gentle Deposition Ultra - Precise Even Distribution Even Droplets No Droplet Loss Non - Drip No Roll - Off Controlled Spray Large - Area Coverage Actual SkinGun™ Spray NO TISSUE CLUMPS

14 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Research. Development. Innovation.

15 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Bioengineering & Cell Biology Regenerative Medicine Medical Device Engineering and Prototyping Regulatory - Centric IP Driven Engineering QMS Support Documentation RenovaCare R&D and Innovation Team 2 MD - PhDs 2 PhDs 1 MBA - Engineer 4 Engineers CellMist ™ and SkinGun ™ Invented, Prototyped, Patented & Clinically Translated RenovaCare R&D Innovation Center SURGERY BIOENGINEERING MANUFACTURING PRODUCT DESIGN QUALITY

16 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 R&D / QMS Clinical Manufacturing Regulatory Partners Enabling Clinical Pathway DATA - DRIVEN PARTNERS WITH AN UNWAVERING FOCUS ON IMPACT

17 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare IP Summary

18 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Cell spray device developed Disposable SkinGun™ Encompass all types of cell tissues or organs Modular handheld spray device for cells Additional IP filings Electronic SkinGun™ IP tested and validated Cell isolation process developed Expanding Our Intellectual Property Closed Cell Isolation System PATENT PROTECTION HAS GROWN SIGNIFICANTLY TO INCLUDE SPRAYING ORGANS AND TISSUES Patent Protection Extending to 2037 2011 2013 2016 2018 2019 2020

19 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Disciplined Pathway & World Class Management

20 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 $1B ~$600 - 700M ~$200 - 300M ~$2B in - patient burns severe second degree operation theater POTENTIAL TWO BILLION DOLLAR MARKET OPPORTUNITY WITHIN THE U.S. RenovaCare Regenerative Cell Therapies Advanced Burn Care Current Market out - patient burns pediatric scalds clinical setting wounds trauma dermatological + gene therapy Future Expanded Markets SKIN EXPANDED INDICATIONS *Based on Company Market Estimates Commercial Market Potential

21 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Regulatory Priorities Planned Clinical Trials Corporate Development Activities Four Burn Center Sites: Q1 2021 FDA IDE Submission: Jul 2020 FDA IDE Cond App: Aug 2020 FDA IDE Final App: Q1 2021 FDA 510(k) Submission: 1H 2021 Hired strategic talent to drive corporate activities, clinical trials, and FDA submissions Expand portfolio through multiple collaborative partnerships and strategic alliance activities Comprehensive financing plan 2020 – 2021 Milestones / Goals KEY TRANSITION ACTIVITIES FOR DEVELOPMENT - STAGE GROWTH

22 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 COMMERCIALIZATION OPERATIONS REGULATORY R&D MANUFACTURING CLINICAL FULLY - INTEGRATED CAPABILITIES Alan L. Rubino CEO / President / Chairman Robert Cook Chief Financial Officer Dr. Robin Robinson Chief Scientific Officer Dr. Jo Schweinle Chief Medical Officer Joseph Sierchio General Counsel Amit Singh Special Projects Dr. Roger Esteban - Vives VP R&D and Product Dev Dr. Rodney Sparks VP Intellectual Property Jean Krebs Quality Affairs MCRA Regulatory Consulting StemCell Systems GmbH Strategic Alliance Partner Mike Lerner Business Counsel Experienced Leadership Team INTELLECTUAL PROPERTY REGENERATIVE MEDICINE | BIOMEDICAL DEVICES | BURNS & WOUNDS QUALITY

23 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Building For Success Focused On Results

24 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 ~$266 Million Market Cap $8.7 Million Cash - on - Hand $8.6 Million Stockholders Equity Closing price at 5 - Jan - 2021: $3.05 Financials as of September 30, 2020 RenovaCare, Inc. Symbol: RCAR $3.5 Million Cash Used In Operations – 9 months ~87 Million Outstanding Shares ~18.1 Million Outstanding Warrants & Options Financial Highlights

25 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Building Shareholder Value RenovaCare: Focused, Growing, Disciplined & Proven ▪ cell isolation and spray technologies ▪ stem cell therapies for acute and chronic wounds, including burns ▪ highly - innovative, proven R&D group (IP, regulatory, clinical) 1 . Focused Portfolio : Cutting - Edge Stem - Cell Spray Therapies 3 . Robust, Expanding, Proven IP Estate 2 . Multiple Growth Drivers 4 . Demonstrated Record : Strategic Commercial Partnerships 5 . Disciplined Capital Allocation with World - Class Management Team ▪ worldwide market demand for self - donated stem cell therapies ▪ diverse therapeutic opportunities for tissue and organ regeneration ▪ portfolio growth in key therapeutic areas and strategic partnerships ▪ sole ownership of all technology with no in - licensing ▪ key technology protections covering methods and devices ▪ core areas focused on differentiated products for unmet needs ▪ clear and focused business development driven by experience ▪ established history of successful strategic longitudinal relationships ▪ well - positioned for government relationships with founding director, BARDA ▪ return on investment driven, time to market obsessive ▪ diversification and strengthening of immediate value - adds ▪ focused investment in strategic business drivers with operational efficiency

26 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Questions & Answers

27

© 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 spray - on stem cells for rapid healing . SkinGun™ & CellMist™ Next Generation Cell Isolation & Ultra - Gentle Cell Spray Symbol: RCAR Thank you for your participation. January 19, 2021 contact@renovacareinc.com +1 888 398 0202 RenovaCare, Inc.